Genetic determinant of metabolic syndrome – a review
DOI:
https://doi.org/10.15584/ejcem.2025.3.18Keywords:
genetics, lifestyle modification, metabolic syndrome, obesityAbstract
Introduction and aim. Metabolic syndrome is a pathological condition that is a combination of insulin resistance, hypertension, dyslipidemia, and abdominal obesity. Every metabolic syndrome trait has an estimated hereditary factor greater than fifty percent. Many mutations related to distinct traits have been successfully identified through genetic studies. With respect to the advancements in our knowledge of the genetics of obesity, it is a major contributor to metabolic syndrome. Metabolic syndrome is associated with many diseases and is closely related to overweight / obesity and lack of activity. Genetic predisposition also plays an important role in it. Therefore, lifestyle modification is the initial and main intervention that can be implemented for such a population. This review pinpoints the literature on the definition of metabolic syndrome, epidemiology, pathogenesis, and its gene polymorphism and treatment approach comprising metabolic syndrome.
Material and methods. The literature review was carried out using databases such as PubMed, Scopus, Google Scholar and the Web of Science for studies looking into metabolic syndrome and its complications. This review provides a comprehensive analysis of the role of genetic and lifestyle changes in the development of metabolic syndrome.
Analysis of the literature. Metabolic syndrome is a collection of diseases that include lower levels of high-density lipoprotein (HDL), increased triglyceride levels (TG), high blood pressure, more waist circumference, and elevated fasting blood glucose. It is closely related to overweight / obesity and lack of activity. Genetic predisposition also plays an important role in it. So lifestyle modification is the initial and main intervention that can be implemented for this population.
Conclusion. Genetic, lifestyle changes, and other environmental changes contribute to the development of metabolic syndrome. Metabolic syndrome leads to many health issues; for a better healthy outcome, lifestyle modifications such as healthy dietary habits, following regular physical activity, quitting smoking and alcohol, balanced weight, stress management are required.
Downloads
References
Alberti KGMM, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: A joint interim statement of the international diabetes federation task force on epidemiology and prevention; National heart, lung, and blood institute; American heart association; World heart fede-ration; International atherosclerosis society; And inter-national association for the study of obesity. Circulation. 2009;120(16):1640-1645. doi: 10.1161/CIRCULATIONA-HA.109.192644
Wang HH, Lee DK, Liu M, Portincasa P, Wang DQH. Novel insights into the pathogenesis and management of the metabolic syndrome. Pediatr Gastroenterol Hepatol Nutr. 2020;23(3). doi: 10.5223/PGHN.2020.23.3.189
Gobato AO, Vasques AC, Zambon MP, Barros Filho Ade A, Hessel G. Metabolic syndrome and insulin resistance in obese adolescents. Rev Paul Pediatr. 2014;32(1):55-62. doi: 10.1590/s0103-05822014000100010
Kleinrok A, Głowa B. The obesity and its meaning in car-diovascular diseases Part 1. Obesity as a risk factor. Prz Med Uniw Rzesz Inst Leków. 2015;13(2):165-172. doi: 10.15584/przmed.2015.2.9
Després JP, Lemieux I, Bergeron J, et al. Abdominal Obe-sity and the Metabolic Syndrome: Contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol. 2008;28(6):1039-1049. doi: 10.1161/ATVBAHA.107. 159228
Saklayen MG. The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep. 2018;20(2):12. doi: 10.1007/ s11906-018-0812-z
Tune JD, Goodwill AG, Sassoon DJ, Mather KJ. Cardiovascular consequences of metabolic syndrome. Translational Research. 2017;183:57-70. doi: 10.1016/j.trsl.2017.01.001
Povel CM, Boer JM, Onland-Moret NC, Dollé ME, Feskens EJ, van der Schouw YT. Single nucleotide polymorphisms (SNPs) involved in insulin resistance, weight regulation, lipid metabolism and inflammation in relation to metabolic syndrome: an epidemiological study. Cardiovasc Diabetol. 2012;11:133. doi: 10.1186/1475-2840-11-133
Noubiap JJ, Nansseu JR, Lontchi-Yimagou E, et al. Global, regional, and country estimates of metabolic syndrome burden in children and adolescents in 2020: a systematic review and modelling analysis. Lancet Child Adolesc Health. 2022;6(3):158-170. doi:10.1016/S2352-4642(21)00374-6
Bhalwar R. Metabolic syndrome: The Indian public health perspective. Med J Armed Forces India. 2020;76(1):8-16. doi: 10.1016/j.mjafi.2019.12.001
Pérez-Martínez P, Mikhailidis DP, Athyros VG, et al. Lifestyle recommendations for the prevention and management of metabolic syndrome: An international panel recommendation. Nutr Rev. 2017;75(5):307-326. doi: 10.1093/ nutrit/nux014
Rana S, Ali S, Wani HA, Mushtaq QD, Sharma S, Rehman MU. Metabolic syndrome and underlying genetic determinants-A systematic review. J Diabetes Metab Disord. 2022;21(1):1095-1104. doi: 10.1007/s40200-022-01009-z
Rochlani Y, Pothineni NV, Kovelamudi S, Mehta JL. Metabolic syndrome: Pathophysiology, management, and modulation by natural compounds. Ther Adv Cardiovasc Dis. 2017;11(8):215-225. doi: 10.1177/1753944717711379
Dhawan D, Sharma S. Abdominal Obesity, Adipokines and Non-communicable Diseases. J Steroid Biochem Mol Biol. 2020;203:105737. doi: 10.1016/j.jsbmb.2020.105737
Safaei M, Sundararajan EA, Driss M, Boulila W, Shapi’i A. A systematic literature review on obesity: Understanding the causes & consequences of obesity and reviewing various machine learning approaches used to predict obesity. Comput Biol Med. 2021;136. doi: 10.1016/j.compbiomed. 2021.104754
Fruh SM. Obesity: Risk factors, complications, and strategies for sustainable long-term weight management. J Am Assoc Nurse Pract. 2017;29:S3-S14. doi: 10.1002/2327-6924.12510
Lin X, Li H. Obesity: Epidemiology, Pathophysiology, and Therapeutics. Front Endocrinol (Lausanne). 2021;12: 706978. doi: 10.3389/fendo.2021.706978
Guo X, Ding Q, Liang M. Evaluation of eight anthropometric indices for identification of metabolic syndrome in adults with diabetes. Diabetes Metab Syndr Obes. 2021;14:1431-1443. doi: 10.2147/DMSO.S294244
Freeman AM, Acevedo LA, Pennings N. Insulin Resistan-ce. In: StatPearls. Treasure Island (FL): StatPearls Publi-shing; August 17, 2023.
Bhattacherjee S, Guha S, Banerjee I, Nath I, Banerjee R, Ray K. A study of insulin resistance and its clinico-metabolic associations among apparently healthy individuals attending a tertiary care hospital. Ann Med Health Sci Res. 2014;4(5):823. doi: 10.4103/2141-9248.141572
Mahaki H, Mansourian M, Meshkat Z, et al. Nanoparticles Containing Oxaliplatin and the Treatment of Colorectal Cancer. Curr Pharm Des. 2023;29(38):3018-3039. doi: 10.2174/0113816128274742231103063738
Brosolo G, Da Porto A, Bulfone L, et al. Insulin Resistance and High Blood Pressure: Mechanistic Insight on the Role of the Kidney. Biomedicines. 2022;10(10). doi: 10.3390/ biomedicines10102374
Fahed G, Aoun L, Zerdan MB, et al. Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. Int J Mol Sci. 2022;23(2):786. doi: 10.3390/ijms23020786
Motamed N, Miresmail SJ, Rabiee B, et al. Optimal cu-toff points for HOMA-IR and QUICKI in the diagnosis of metabolic syndrome and non-alcoholic fatty liver dise-ase: A population based study. J Diabetes Complications. 2016;30(2):269-274. doi: 10.1016/j.jdiacomp.2015.11.019
Haile K, Haile A, Timerga A. Predictors of lipid profile abnormalities among patients with metabolic syndrome in southwest ethiopia: A cross-sectional study. Vasc Health Risk Manag. 2021;17:461-469. doi: 10.2147/VHRM.S319161
Blaton VH, Korita I, Bulo A, et al. How is metabolic syndro-me related to dyslipidemia? Biochemia Medica. 2008;18(1): 14-24.
Janani J, Lakshmanan K, Gopalakrishnan S. Unveiling the atherogenic lipoprotein particle: A case-control study. Rom J Diabetes Nutr Metab Dis. 2023;30(4):398-402. doi: 10.46389/rjd-2023-1384
Carr MC, Brunzell JD. Abdominal obesity and dyslipidemia in the metabolic syndrome: Importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. In: Journal of Clinical Endocrinology and Metabolism. 2004;89:2601-2607. doi: 10.1210/jc.2004-0432
Stanciu S, Rusu E, Miricescu D, et al. Links between Metabolic Syndrome and Hypertension: The Relationship with the Current Antidiabetic Drugs. Metabolites. 2023;13(1):87. doi: 10.3390/metabo13010087
Lalwani RK, Shah JD, Chatterjea T, Nadakuduru PR, Erande S. Prevalence of depression in Indian patients with type 2 diabetes mellitus and/or hypertension: DEPTH Study. Eur J Clin Expl Med. 2019;17(4):315-325. doi: 10.15584/ ejcem.2019.4.5
Soleimani M, Barone S, Luo H, Zahedi K. Pathogenesis of Hypertension in Metabolic Syndrome: The Role of Fructose and Salt. Int J Mol Sci. 2023;24(5):4294. doi: 10.3390/ ijms24054294
Chaimati S, Shantavasinkul PC, Sirivarasai J, Sritara P. Effects of AGT and AGTR1 Genetic Polymorphisms and Changes in Blood Pressure Over a Five-Year Follow--Up. Risk Manag Healthc Policy. 2023;16:2931-2942. doi: 10.2147/RMHP.S442983
Ho CY, Lee JI, Huang SP, Chen SC, Geng JH. A Genome-Wide Association Study of Metabolic Syndrome in the Taiwanese Population. Nutrients. 2024;16(1):77. doi: 10.3390/nu16010077
Wan JY, Goodman DL, Willems EL, et al. Genome-wide association analysis of metabolic syndrome quantitative traits in the GENNID multiethnic family study. Diabetol Metab Syndr. 2021;13(1):59. doi: 10.1186/s13098-021-00670-3
Nagrani R, Foraita R, Gianfagna F, et al. Common genetic variation in obesity, lipid transfer genes and risk of Metabolic Syndrome: Results from IDEFICS/I.Family study and meta-analysis. Sci Rep. 2020;10(1):7189. doi: 10.1038/ s41598-020-64031-2
Gu HF. Biomarkers of Adiponectin: Plasma Protein Varia-tion and Genomic DnA Polymorphisms. 2009. http://www. la-press.com.http://www.la-press.com. Accessed June 20, 2024.
Ghoshal K. Adiponectin: Probe of the molecular paradigm associating diabetes and obesity. World J Diabetes. 2015;6(1):151. doi: 10.4239/wjd.v6.i1.151
de Luis Roman D, Izaola Jauregui O, Primo Martin D. The Polymorphism rs17300539 in the Adiponectin Promoter Gene Is Related to Metabolic Syndrome, Insulin Resistance, and Adiponectin Levels in Caucasian Patients with Obesity. Nutrients. 2023;15(24):5028. doi: 10.3390/ nu15245028
Kaur H, Badaruddoza B, Bains V, Kaur A. Genetic association of ADIPOQ gene variants (-3971A>G and +276G>T) with obesity and metabolic syndrome in north Indian punjabi population. PLoS One. 2018;13(9):e0204502. doi: 10.1371/journal.pone.0204502
Shramko II, Ageeva ES, Maliy KD, et al. Association be-tween Adiponectin and Leptin Receptor Genetic Polymorphisms and Clinical Manifestations of Metabolic Syndrome. J Diabetes Res. 2022;2022. doi: 10.1155/2022/9881422
Santos JL, Krause BJ, Cataldo LR, et al. PPARGC1A gene promoter methylation as a biomarker of insulin secretion and sensitivity in response to glucose challenges. Nu-trients. 2020;12(9):1-15. doi: 10.3390/nu12092790
Taghvaei S, Saremi L, Babaniamansour S. Computational Analysis of Gly482Ser Single-Nucleotide Polymorphism in PPARGC1A Gene Associated with CAD, NAFLD, T2DM, Obesity, Hypertension, and Metabolic Diseases. PPAR Res. 2021;2021. doi: 10.1155/2021/5544233
Csép K, Szigeti E, Vitai M, Korányi L. The ppargc1a - Gly482Ser polymorphism (RS8192678) and the metabolic syndrome in a central romanian population. Acta Endocrinol (Copenh). 2017;13(2):161-167. doi: 10.4183/ aeb.2017.161
Du F, Yang KJ, Piao LS. Correlation between PPARGC1A gene rs8192678 G>A polymorphism and susceptibility to type-2 diabetes. Open Life Sci. 2019;14(1):43-52. doi: 10.1515/biol-2019-0006
Qi Q, Kilpeläinen TO, Downer MK, et al. FTO genetic va-riants, dietary intake and body mass index: insights from 177,330 individuals. Hum Mol Genet. 2014;23(25):6961-6972. doi: 10.1093/hmg/ddu411
Harun NS, Wan Jusoh AF, Rohin MAK, Yahaya R, Nik Him NAS, Zahary MN. The contribution of FTO rs9939609 and RETN rs1862513 polymorphisms in pre-disposing resettled indigenous (Orang Asli) Temiar to metabolic syndrome. Egyptian Journal of Medical Human Genetics. 2023;24(1):44. doi: 10.1186/s43042-023-00425-x
Khella MS, Hamdy NM, Amin AI, El-Mesallamy HO. The (FTO) gene polymorphism is associated with metabolic syndrome risk in Egyptian females: A case- control study. BMC Med Genet. 2017;18(1):101. doi: 10.1186/s12881-017-0461-0
Liguori R, Labruna G, Alfieri A, et al. The FTO gene polymorphism (rs9939609) is associated with metabolic syndrome in morbidly obese subjects from southern Italy. Mol Cell Probes. 2014;28(4):195-199. doi: 10.1016/j. mcp.2014.03.004
Al-Hussaniy HA, Alburghaif AH, Naji MA. Leptin hormone and its effectiveness in reproduction, metabolism, immunity, diabetes, hopes and ambitions. J Med Life. 2021;14(5):600-605. doi: 10.25122/jml-2021-0153
Chen MC, Wang JH, Lee CJ, Hsu BG. Association betwe-en hyperleptinemia and cardiovascular outcomes in patients with coronary artery disease. Ther Clin Risk Manag. 2018;14:1855-1862. doi: 10.2147/TCRM.S172231
Mirrakhimov E, Bektasheva E, Isakova J, et al. Associa-tion of leptin receptor gene Gln223Arg polymorphism with insulin resistance and hyperglycemia in patients with metabolic syndrome. Archives of Medical Science. 2024;20(1):54-60. doi: 10.5114/aoms/170121
Ortega FL, Camberos AM, Arredondo MI, Magalla-nes NG, Meraz EA. LEP (G2548A-G19A) and ADIPOQ (T45G-G276T) gene polymorphisms are associated with markers for metabolic syndrome. Diabetol Metab Syndr. 2023;15(1). doi: 10.1186/s13098-023-01215-6
Hatefi Z, Soltani G, Khosravi S, Kazemi M, Salehi A, Salehi R. Micro R-410 Binding Site Single Nucleotide Polymorphism rs13702 in Lipoprotein Lipase Gene is Effective to Increase Susceptibility to Type 2 Diabetes in Iranian Po-pulation. Adv Biomed Res. 2018;7(1):79. doi: 10.4103/abr. abr_286_16
Hsu CS, Chang ST, Nfor ON, et al. Association of metabolic syndrome with aerobic exercise and lpl rs3779788 polymorphism in taiwan biobank individuals. Diabetes Metab Syndr Obes. 2021;14:3997-4004. doi: 10.2147/DMSO. S328308
Bora K, Pathak MS, Borah P, Hussain MI, Das D. Single nucleotide polymorphisms of APOA1 gene and their relationship with serum apolipoprotein A-I concentrations in the native population of Assam. Meta Gene. 2016;7:20-27. doi: 10.1016/j.mgene.2015.10.005
de Luis DA, Izaola O, Primo D, Aller R. Implication of the rs670 variant of APOA1 gene with lipid profile, serum adi-pokine levels and components of metabolic syndrome in adult obese subjects. Clin Nutr. 2019;38(1):407-411. doi: 10.1016/j.clnu.2017.12.007
Supajaree P, Chanprasertyothin S, Chattranukulchai Shantavasinkul P, Sritara P, Sirivarasai J. Association between ApoA1 Gene, Plasma Lipid Profile, hsCRP Level, and Risk of Arterial Stiffness in Thai Elderly. Adv Prev Med. 2022;2022:1-8. doi: 10.1155/2022/4930033
Hosseini-Esfahani F, Mirmiran P, Daneshpour MS, et al. Dietary patterns interact with APOA1/APOC3 polymorphisms to alter the risk of the metabolic syndrome: the Tehran Lipid and Glucose Study. Br J Nutr. 2015;113(4): 644-653. doi: 10.1017/S0007114514003687
Zaki ME, Amr KS, Abdel-Hamid M. Evaluating the as-sociation of APOA2 polymorphism with insulin resistance in adolescents. Meta Gene. 2014;2(1):366-373. doi: 10.1016/j.mgene.2014.04.007
Zaki ME, Amr KS, Abdel-Hamid M. APOA2 polymorphism in relation to obesity and lipid metabolism. Cholesterol. 2013;2013:1-5. doi: 10.1155/2013/289481
Kim M, Lee S, Cho E, Hong KW, You SJ, Choi HJ. CETP and APOA2 polymorphisms are associated with weight loss and healthy eating behavior changes in response to digital lifestyle modifications. Sci Rep. 2023;13(1):21615. doi: 10.1038/s41598-023-48823-w
Giulio Marchesini G. Lifestyle modification in the management of the metabolic syndrome: achievements and challenges. Diabetes Metab Syndr Obes. 2010;3:373-385. doi: 10.2147/dmsott.s13860
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
